Drug Shortage Report for TEVA-RISEDRONATE
| Report ID | 147714 |
| Drug Identification Number | 02298384 |
| Brand name | TEVA-RISEDRONATE |
| Common or Proper name | RISEDRONATE 30MG TAB |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | RISEDRONATE SODIUM |
| Strength(s) | 30MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 30 |
| ATC code | M05BA |
| ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | |
| Actual start date | 2021-10-20 |
| Estimated end date | 2022-01-31 |
| Actual end date | 2021-12-14 |
| Shortage status | Resolved |
| Updated date | 2021-12-17 |
| Company comments | Shortdated Lots |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2021-12-17 | French | Compare |
| v3 | 2021-12-17 | English | Compare |
| v2 | 2021-10-21 | French | Compare |
| v1 | 2021-10-21 | English | Compare |
Showing 1 to 4 of 4